(Commercial Excellence, Data & Digital , BD&L)- DESIGN go-to-market model with performance matrix to evolve promotion and solution-based operation in entire field transformation journey.- PIONEER use case series (channel sequencing & segmented messages) to identify capability level, customer needs and value of engagement and shape differentiated OCE approach in line with digital transformation core values.- REINFORCE data-driven decision making through bring data to users in… Show more (Commercial Excellence, Data & Digital , BD&L)- DESIGN go-to-market model with performance matrix to evolve promotion and solution-based operation in entire field transformation journey.- PIONEER use case series (channel sequencing & segmented messages) to identify capability level, customer needs and value of engagement and shape differentiated OCE approach in line with digital transformation core values.- REINFORCE data-driven decision making through bring data to users in analytics excellence to interface insights generating.- STREAMLINE digital solutions in engagement, patient care and financial support aspects.- ANALYZE potential partners to seek synergistic BD&L model to optimize oncology mature brandsHighlight: improve learning indicators in orchestration, customer coverage level and channel performance. Show less

- LEAD BEST sequential strategic portfolio strategy (KISQALI, PIQRAY, AFINITOR) as curated packages for different patient segments in HR+MBC treatment journey.- DEVELOP internal and external alliance (TESTING platforms with QIAGEN and ACT Genomics) to create launch excellence (PIQRAY).- COLLABROATE with brand team to achieve goal of KISQALI post-menopausal reimbursement criteria relaxation to unleash growth opportunity.- CHAMPION innovative platform ( post-reimbursement patient… Show more - LEAD BEST sequential strategic portfolio strategy (KISQALI, PIQRAY, AFINITOR) as curated packages for different patient segments in HR+MBC treatment journey.- DEVELOP internal and external alliance (TESTING platforms with QIAGEN and ACT Genomics) to create launch excellence (PIQRAY).- COLLABROATE with brand team to achieve goal of KISQALI post-menopausal reimbursement criteria relaxation to unleash growth opportunity.- CHAMPION innovative platform ( post-reimbursement patient access platform) to provide out-of-pocket solution across pre-menopausal and post-menopausal beyond 24 months restriction patient segments.- ULITLIZE content marketing (Rep-Triggered email) as engagement tool in remote settingHighlight: Successfully achieve 2021 KISQALI in-market sales over $20m, total portfolio over $38m. Show less

- TRANSFORM new dedicated commercial model (4 FTEs) for VOTRIENT within 6 months to meet P&L optimization goal and enterprise priority as restructure BC commercial team independency.- OPTIMIZE life cycle management by aligning key customers values with potential NOVARTIS business development (ex. PSMA-Radioligand therapy in prostate cancer, PIK3CA inhibitors in ovary cancer).Highlight: successfully achieve profit target ($4.2m).

- STRATEGIZE counter plan (VOTRIENT RCC ) to expand the 1st line market with best TKI-TKI-IO treatment scenario.- ACCELERATE selected key Center of Excellence (VOTRIENT STS) to maximize business potential as patient-centric multidisciplinary team (MDT) establishment .Achievements • Achieved VOTRIENT YTD sales target 105% and 18.0% growth versus actual 17’.• Maximize brand and corporate SOV through successfully launching public awareness video and enhance key stakeholder… Show more - STRATEGIZE counter plan (VOTRIENT RCC ) to expand the 1st line market with best TKI-TKI-IO treatment scenario.- ACCELERATE selected key Center of Excellence (VOTRIENT STS) to maximize business potential as patient-centric multidisciplinary team (MDT) establishment .Achievements • Achieved VOTRIENT YTD sales target 105% and 18.0% growth versus actual 17’.• Maximize brand and corporate SOV through successfully launching public awareness video and enhance key stakeholder engagement to strengthen brand loyalty.• 2018 10th EGM best practice winner by vote of the regional panel Show less

- STRATEGIZE counter plan (VOTRIENT RCC ) to expand the 1st line market with best TKI-TKI-IO treatment scenario.- ACCELERATE selected key Center of Excellence (VOTRIENT STS) to maximize business potential as patient-centric multidisciplinary team (MDT) establishment.Achievements • Achieved VOTRIENT YTD sales target 105% and 44.0% growth versus actual 16’.• Significantly Increased RCC patient share from 15% to 25% by maximizing window of reimbursement… Show more - STRATEGIZE counter plan (VOTRIENT RCC ) to expand the 1st line market with best TKI-TKI-IO treatment scenario.- ACCELERATE selected key Center of Excellence (VOTRIENT STS) to maximize business potential as patient-centric multidisciplinary team (MDT) establishment.Achievements • Achieved VOTRIENT YTD sales target 105% and 44.0% growth versus actual 16’.• Significantly Increased RCC patient share from 15% to 25% by maximizing window of reimbursement relaxation.• Increase brand SOV by disseminating the updated real world evidence through video clips and livestream in several commercial events.• Successfully Launched RCC global standalone virtue meeting for 28 physicians and participant rate over 70%. Show less

• Products : VOTRIENT(Soft tissue sarcoma), TYKERB (Breast cancer), ZOMETA (Breast cancer/Prostate cancer) - STRATEGIZE counter plan (VOTRIENT RCC ) to expand the 1st line market with best TKI-TKI-IO treatment scenario.- ACCELERATE selected key Center of Excellence (VOTRIENT STS) to maximize business potential as patient-centric multidisciplinary team (MDT) establishment.

- DRIVE key brand (ZOMETA) growth momentum through sharpening competitive brand essentials- UNLEASH windows of reimbursement opportunity (AFINITOR BC) through driving robust pre-approval case to support customer needs and priority.- STREGTHEN differentiated messages (VOTRIENT RCC) to overcome market restrictions (TKI-mTOR vs. TKI-TKI)

Responsibilities • Territory : Mackay Memorial Hospital(All branches, except Taitung), Cathay General Hospital(all branches), NTUH Hsin-Chu Branch • Products: AFINITOR (Breast cancer/Renal cell carcinoma), VOTRIENT(Renal cell carcinoma/Soft tissue sarcoma), TYKERB (Breast cancer), FEMARA (Breast cancer), ZOMETA (Breast cancer/prostate cancer), VOTUBIA (Tuberous sclerosis complex).

- IDENTIFY market trends to build a sales pipeline for medium/long term in accordance with targets.- CREATE roadmap for generics pipeline (Oncology and Psychology) through integrating product development matrix in R&D, manufacturing, patent, sourcing, and sales operation.

- OVERSEE patient’s condition to ensure all issues (drug-related problems) are being treated appropriately within critical care teamwork.- MASTER proficiency in preceptor roles and actively emulates education/mentorship skills.